Uncategorized

FDA panel confronting peptide controversy

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The FDA is weighing a politically charged decision on compounded peptides, Revolution Medicines is advancing a promising pancreatic cancer drug toward approval, and new evidence suggests Merck’s Ebola vaccine may help blunt the DRC’s Bundibugyo outbreak.

Read the rest…

Read More

Published

on

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The FDA is weighing a politically charged decision on compounded peptides, Revolution Medicines is advancing a promising pancreatic cancer drug toward approval, and new evidence suggests Merck’s Ebola vaccine may help blunt the DRC’s Bundibugyo outbreak.

Read the rest…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version